We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Mount Sinai Establishes Center for Cardiovascular Medical Devices

By HospiMedica International staff writers
Posted on 16 Jul 2014
Print article
Image: Dr. David Adams and Dr. Julie Swain of CMeD (Photo courtesy of Mount Sinai Heart).
Image: Dr. David Adams and Dr. Julie Swain of CMeD (Photo courtesy of Mount Sinai Heart).
Mount Sinai Heart (New York, NY, USA) has created an innovative Center for Medical Devices (CMeD) to advance the field of cardiovascular medicine and accelerate the delivery of promising medical devices to cardiac patients.

Located at the Icahn School of Medicine at Mount Sinai (New York, NY, USA), the CMeD will help further develop technologies and test medical devices in advanced clinical trials toward the strategic goal of regulatory approval, thus accelerating cardiac devices delivery to patients who need them. Services available through CMeD include cardiac medical device assessment and evaluation, regulatory approval strategies, advanced clinical trial design, data interpretation, assistance with FDA submissions, and potential access to clinical testing at Mount Sinai.

In addition, CMeD will be a training center for future medical professionals wishing to gain experience in advanced clinical trial design and evaluation of medical devices. To do so, Mount Sinai Heart has Recruited Julie Swain, MD, a practicing cardiothoracic surgeon for more than 25 years and clinical trials expert who has consulted for the US Food and Drug Administration (FDA). In addition to her role as Director of CMeD, Dr. Swain will serve as Professor of Cardiovascular Surgery and Director of Clinical Research in the Department of Cardiovascular Surgery at Mount Sinai.

“Our mission at CMeD will be to provide the critical expertise and guidance needed by medical device companies, inventors, and researchers to further develop and test innovative cardiac medical devices that show promise to advance the field of cardiovascular medicine and the heart health of patients around the globe,” said Dr. Swain. “If you need help at any stage of your promising cardiac medical device’s research and development, ranging from the earliest development of your medical device to the final regulatory FDA approval, our experienced team at CMeD at Mount Sinai Heart can help.”

“Dr. Swain is internationally acclaimed for her leadership as the key advisor on cardiac device trial design and data interpretation for the Food and Drug Administration over the past decade,” commented David Adams, MD, chairman of the department of cardiovascular surgery. “She has been at the center of every major cardiac device trial in this role, and is thus uniquely positioned to lead our medical device program going forward. I expect this program to be a national level resource that will bring us access to a number of cutting edge clinical research opportunities, and assure our position as a leader in this space.”

Mount Sinai Heart is ranked No. 13 for heart services by US News & World Report, and is home to the largest catheterization laboratory in the United States. Considered a world leader in all facets of cardiology care and research, it is also a world leader in mitral valve reconstruction.

Related Links:

Mount Sinai Heart
Icahn School of Medicine at Mount Sinai


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Medical Gas Blender
BlenderBuddy 1

Print article

Channels

Surgical Techniques

view channel
Image: Computational models can predict future structural integrity of a child’s heart valves (Photo courtesy of 123RF)

Computational Models Predict Heart Valve Leakage in Children

Hypoplastic left heart syndrome is a serious birth defect in which the left side of a baby’s heart is underdeveloped and ineffective at pumping blood, forcing the right side to handle the circulation to... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.